Organization of treatment and rehabilitation in Germany.
Complete medical support.
Complete medical support.
+49 176 17917001
All departments
Spondylodiscitis is an infectious-inflammatory disease of the spine affecting the intervertebral disc (discitis) and adjacent vertebral bodies (spondylitis). This is a dangerous condition that, without timely treatment, leads to vertebral structure destruction, instability, abscesses, and neurological complications. Spondylodiscitis treatment in Germany includes targeted antibiotic therapy, modern surgery, and innovative MIBRAR® therapy for regeneration of damaged tissues after infection clearance.
Infection reaches the spine through three pathways. The hematogenous route — via bloodstream from another infection site (urinary tract, lungs, skin, heart) — is the most common (70–80%). The iatrogenic route follows spinal surgery, punctures, or epidural injections (15–25%). The contiguous route involves spread from adjacent tissues (paravertebral abscess). The most common pathogens include Staphylococcus aureus (50–60%), gram-negative bacteria (E. coli, Pseudomonas), Mycobacterium tuberculosis (in endemic regions), and fungi (in immunocompromised patients). The infection destroys the disc (which has no blood supply and cannot effectively fight infection), then spreads to vertebral bodies causing their destruction.
The leading risk factors include diabetes mellitus (up to 30% of spondylodiscitis patients), immunosuppression (HIV, corticosteroid use, chemotherapy), intravenous drug use, chronic infections (urinary tract, lung, skin, endocarditis), previous spinal surgery (post-operative spondylodiscitis), advanced age (reduced immunity), and chronic kidney disease with dialysis.
Spondylodiscitis is often diagnosed late — 2–6 months after onset — due to non-specific symptoms. The main manifestation is back pain that is constant, deep, unrelated to movement (unlike osteochondrosis), worsening at night and not relieved by rest. Fever ranges from low-grade to high (38–40°C), though it may be absent in elderly and immunocompromised patients. General malaise includes weakness, sweating, and weight loss. Local tenderness appears with percussion over spinous processes. Back stiffness from reflexive muscle tension is common.
Complications include epidural abscess with spinal cord compression causing paresis and pelvic dysfunction, psoas abscess with infection spread to the iliopsoas muscle, vertebral body destruction with pathological fracture and deformity, spinal instability, and sepsis.
Laboratory tests reveal elevated ESR (in 90% of patients), CRP (the most sensitive marker), leukocytes, and procalcitonin. Blood cultures are positive in 30–50%. Contrast-enhanced MRI is the gold standard with 96% sensitivity and 93% specificity, showing vertebral body and disc edema (T2 hyperintensity, T1 hypointensity), contrast enhancement, and abscesses. CT evaluates bone destruction and surgical planning. PET/CT with 18F-FDG aids in uncertain diagnoses and monitoring. CT-guided biopsy obtains material for bacteriological testing — performed before antibiotic initiation! Pathogen identification is key to targeted treatment. Radiography shows late changes (2–4 weeks): endplate destruction and disc height loss.
The foundation of uncomplicated spondylodiscitis treatment is targeted antibiotic therapy. Intravenous antibiotics are administered for 2–4 weeks (inpatient), followed by oral transition. Oral antibiotics continue for 6–12 weeks total, with selection based on the pathogen. Immobilization with a brace limits affected segment mobility. Monitoring includes weekly CRP checks and MRI at 4–6 and 12 weeks.
| Pathogen | Antibiotic | Duration |
|---|---|---|
| S. aureus (MSSA) | Flucloxacillin IV → rifampicin + fluoroquinolone | 6–12 weeks |
| MRSA | Vancomycin / daptomycin + rifampicin | 6–12 weeks |
| Gram-negative | Cephalosporins IV → fluoroquinolones | 6–8 weeks |
| Tuberculosis | 4-drug regimen (isoniazid, rifampicin, pyrazinamide, ethambutol) | 9–12 months |
Conservative treatment is effective in 70–80% of patients with early detection.
Spondylodiscitis is included in the indications for MIBRAR® technology. Prof. Babayan's method is applied after active infection clearance — during the structural restoration phase. MIBRAR® achieves destroyed disc regeneration through intradiscal ARC transplantation (RRBSW method), restoring disc height and structure to prevent segment collapse and the need for fusion. Vertebral body regeneration uses growth factors and stem cells to stimulate bone tissue restoration in destruction zones. The powerful anti-inflammatory effect of ARC's anti-inflammatory factors helps suppress residual inflammation without cortisone. ARC also has proven antimicrobial action (data from Prof. Babayan's book). Segment stabilization through disc and ligament restoration prevents instability without metal hardware.
The procedure is outpatient, without anesthesia, under Sono Control Arm™ or Cyber-Navi-Hand™ guidance. Performed strictly after verified infection clearance (normalized CRP, follow-up MRI).
Surgery for spondylodiscitis is indicated for epidural abscess with neurological deficit (emergency!), pronounced vertebral destruction with instability or deformity, antibiotic therapy failure (rising CRP, enlarging abscess on MRI), and need for bacteriological sampling (with negative blood cultures). Methods include abscess drainage (percutaneous CT-guided or open), debridement with stabilization (infected tissue removal, cage and transpedicular fixation placement — anterior approach with posterior fixation preferred), and minimally invasive fixation (percutaneous transpedicular fixation for instability without gross destruction).
Recovery includes continued antibiotic therapy to full course completion, brace wearing for 8–12 weeks, gradual muscular corset strengthening exercise therapy after infection clearance, CRP and MRI monitoring at 3, 6, and 12 months, and treatment of underlying disease (diabetes, immunodeficiency).
| Service | Price, € | Note |
|---|---|---|
| Diagnostics (MRI + laboratory + biopsy) | 4,000–8,000 | 2–3 days |
| Inpatient antibiotic therapy (2–4 wks) | 10,000–20,000 | inpatient |
| MIBRAR® therapy (after clearance) | on request | outpatient |
| Surgical debridement + stabilization | 25,000–45,000 | 7–14 days inpatient |
All treatment prices in Germany.
Germany offers early diagnosis with MRI and PET/CT, CT-guided biopsy for pathogen identification, targeted antibiotic therapy following international protocols, MIBRAR® therapy for damaged structure regeneration after infection clearance, minimally invasive surgery for complications, and a complete treatment and monitoring cycle at world-class clinics.
Spondylodiscitis is a serious condition requiring expert management. Contact us — we will organize treatment at the best clinics in Germany.
+49 176 17917001 
Or send us a message:
